SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor Corp is trending as investors digest a major partnership between AWS and Cerebras, with the market increasingly recognizing Vicor's role in providing the high-performance power delivery systems essential for Cerebras's AI hardware. Traders are actively monitoring the stock's high volatility and technical setups, while community sentiment remains split between excitement over Vicors AI data center exposure and caution regarding its valuation and recent price swings.

Invesco Capital Management LLC - PowerShares UltraShort Lehman 20+ Year Treasury ProShares 2x Shares

ProShares UltraShort 20+ Year Treasury ETF

The community is actively discussing a bond market selloff, with traders utilizing $TBT to hedge against rising long-term Treasury yields and potential stagflationary pressures. Investors are closely monitoring hawkish Fed rhetoric, deficit concerns, and increased debt issuance as primary catalysts for the ongoing volatility in the bond complex.

VeChain, founded in 2015, is a sustainability-focused blockchain driving mass adoption of Web3. Its energy-efficient VeChainThor chain delivers fast, low-cost transactions, making blockchain accessible to millions worldwide. With partnerships including UFC, BCG, and Walmart, and over 2 million active users on VeBetter-powered apps, VeChain is proving real-world impact at scale.  In 2024, the VeChain Renaissance upgrade was launched, introducing Ethereum compatibility, dPoS consensus, and dynamic gas fees. It cut VTHO inflation and introduced StarGate NFT staking, where users lock VET to mint transferable NFTs that earn VTHO, can be delegated to validators, and serve as governance instruments. The upgrade also added new eco node tiers, lowering entry barriers while keeping rewards across higher staking levels.  By combining adoption, upgraded tokenomics, and inclusive staking, VeChain is positioning itself as a leading blockchain where usage, growth, and rewards fuel long-term value creation.

Vechain

VeChain (VET) is currently trending as holders weigh long-term utility-based catalysts like the upcoming Hayabusa upgrade and EU Digital Product Passport mandates against frustration over prolonged price stagnation. While community sentiment is heavily polarized between those accumulating at current lows and others expressing extreme pessimism over recent performance, active discussions remain focused on institutional partnerships and the potential for a long-awaited shift in network activity.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA) is trending as investors debate the potential of its high-throughput blockchain technology and pending fiat anchor developments amid volatile price action. While the community is split between bullish sentiment regarding institutional ties and skepticism over whether the project can meet its ambitious long-term scaling milestones, many are actively using price dips as an opportunity to accumulate.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as the community debates the project's long-term potential amid significant price volatility and recent negative sentiment surrounding the ASI token migration. While some investors are aggressively accumulating at current levels, betting on the utility of decentralized AI agents and strategic partnerships, others are concerned about ongoing FUD and are waiting for clearer signs of a sustained trend reversal.

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Lipocine Inc

Lipocine is currently in focus as investors await critical Phase 3 topline results for its oral PPD treatment, LPCN 1154, expected early in April. While the community remains divided on the risks of pre-results dilution, discussions are heavily centered on the potential for this drug to disrupt the PPD market by offering a more convenient, home-based alternative to existing IV-based therapies.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy Corp

Constellation Energy is experiencing heightened volatility and intense trader debate as market participants navigate a broader rotation out of high-multiple power generation names. While the company's long-term thesis remains tied to critical baseload power for AI data centers and nuclear infrastructure, the stock is currently facing pressure from valuation concerns, interest rate sensitivity, and policy uncertainty regarding capacity auctions.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano is trending as community members rally behind its real-world business integration, specifically highlighting revenue generated from a physical food truck operation that fuels token buybacks. Investors are actively discussing its multi-pronged ecosystem, which includes a staking arena and meme hub, while maintaining high engagement on social platforms to promote the project's long-term utility.

Melco Resorts & Entertainment Ltd. engages in the management and development of casino gaming and entertainment resort facilities. The firm focuses on the administration of Mocha Clubs, Altira Macau, City of Dreams, Studio City, and City of Dreams Manila. It operates through the following geographical segments: Macau, the Philippines, Cyprus, and Corporate and Other. The company was founded by Yau Lung Ho in December 2004 and is headquartered in Hong Kong.

Melco Resorts & Entertainment Ltd - ADR

Melco Crown Entertainment Ltd.

Melco Resorts is seeing heightened activity as analysts debate its valuation amid broader Macau gaming sector recovery and persistent concerns over debt levels and market share. Community sentiment is mixed, with some traders optimistic about long-term potential following recent positive GGR data, while others express frustration over the stock's volatility and the operational headwinds in its non-Macau assets.

TransDigm Group, Inc. engages in the design, production, and supply of aircraft components. It operates through the following segments: Power and Control, Airframe, and Non-Aviation. The Power and Control segment includes electromechanical actuators and controls, ignition systems and engine technology, specialized pumps and valves, and power conditioning devices. The Airframe segment covers engineered latching and locking devices, engineered rods, engineered connectors, and elastomer sealing solutions. The Non-Aviation segment involves off-road vehicle suppliers and subsystem suppliers, child restraint system suppliers, and satellite and space system suppliers. The company was founded by W. Nicholas Howley and Douglas W. Peacock in 1993 and is headquartered in Cleveland, OH.

Transdigm Group Incorporated

TransDigm Group is currently trending as investors focus on its aggressive M&A strategy, including the recent $960 million acquisition of Stellant Systems to bolster its aerospace and defense aftermarket portfolio. While the community remains impressed by the company's proprietary component moats and high margins, active discussions are highlighting concerns over its significant debt levels and high valuation relative to earnings growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel...

TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00

TD Cowen upped their price objective on Biohaven from $15.00 to $30.00 and gave the stock a "buy" rating in a research note on Wednesday...

<ul class="summary-bullets"><li>Xenon plans to submit a new drug application for azetukalner to the U.S. Food and Drug Administration for the treatment of focal onset seizures in the third quarter of 2026.</li><li>CEO Ian Mortimer said that the trial results “exceeded expectations.”</li><li>Raymond James, meanwhile, kept a ‘Strong Buy’ rating on Biohaven shares following competitor Xenon’s data readout.</li></ul><p><br>Xenon Pharmaceuticals Inc. (XENE) on Monday announced that it has commenced an underwritten public offering of $500 million of its common shares on the heels of the company announcing positive results from a trial of azetukalner in focal onset seizures (FOS).</p><p>The company said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to a placebo.</p><p>Shares of XENE closed 50% higher in the regular hours of trading.</p><h2 class="st-heading-2">Trial Data</h2><p>With the higher 25 mg dose, a 53.2% median percent change from baseline in monthly FOS frequency was observed, compared with 10.4% for the placebo, the company said.</p><p>Azetukalner also demonstrated a safety and tolerability profile consistent with prior studies, prompting the company to plan submitting a new drug application to the U.S. Food and Drug Administration (FDA) for the treatment of focal onset seizures in the third quarter of 2026.</p><p>CEO Ian Mortimer said that the trial results “exceeded expectations.”</p><p>“Epilepsy is one of the most common neurological diseases, and foundational antiseizure medications do not provide sufficient seizure control for up to 50% of patients, so we are very optimistic about the opportunity for azetukalner to meaningfully shift the epilepsy treatment paradigm,” said CMO Chris Kenney.</p><p>Focal onset seizures, or epilepsy, originate in one localized area of the brain, causing symptoms based on that specific region.</p><h2 class="st-heading-2">Wall Street Reaction</h2><p>Following the trial data announcement, several analysts hiked their price targets on the stock, while also reflecting on the news’ impact on the shares of Biohaven (<a href="https://stocktwits.com/symbol/BHVN">BHVN</a>), which is developing an investigational drug Opakalim for epilepsy, depression, and pain.</p><p>Jefferies raised the firm's price target on Xenon Pharmaceuticals to $100 from $65 and kept a ‘Buy’ rating on the shares. The firm said it thinks azetukalner has the attributes of a top-selling epilepsy pill, driven by best-in-class focal epilepsy data. In 2026, Xenon shares could grind higher as Big Pharma interest rises and as the Street gauges azetuklaner's peak sales potential, the analyst told investors in a research note.</p><p>RBC Capital raised the firm's price target on Xenon Pharmaceuticals to $80 from $59 and kept an ‘Outperform’ rating on the shares, citing a belief that today's "strong" azetukalner data further increases the likelihood that the drug will be approved. The firm, which now estimates 90% odds of success, also sees higher market uptake than previously anticipated and greater potential for the drug to be priced at a premium.</p><h2 class="st-heading-2">Biohaven Still Holds Chance</h2><p>Raymond James, meanwhile, kept a ‘Strong Buy’ rating on Biohaven shares following competitor Xenon’s data readout. Azetukalner showed efficacy in-line with expectations, but with a meaningful safety disadvantage, giving opakalim room to differentiate, it said. The firm believes the results continue to highlight an opportunity for opakalim, or BHV-7000, which has shown meaningful evidence of efficacy with better safety and tolerability.</p><p>Raymond James expects Biohaven to present topline results from the first pivotal trial for opakalim, testing a 25 mg and 50 mg dose, in the second half of 2026, which will more concretely establish the target product profile.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around XENE stock rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/XENE">XENE stock</a> has gained 83% over the past 12 months.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vrtx-soars-in-extended-hours-after-experimental-drug-shows-positive-changes-in-autoimmune-kidney-disease/cZdVDGuRIed">VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Biohaven logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.

Equity

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.


Biohaven (NYSE:BHVN) Shares Gap Up - Time to Buy?

Biohaven (NYSE:BHVN) Shares Gap Up - Here's Why...

TD Asset Management Inc Cuts Stake in Biohaven Ltd. $BHVN

TD Asset Management Inc lowered its stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 53.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The...

Biohaven (NYSE:BHVN) Given New $10.00 Price Target at HC Wainwright

HC Wainwright dropped their price objective on shares of Biohaven from $11.00 to $10.00 and set a "neutral" rating on the stock in a research note on Wednesday...

Biohaven (NYSE:BHVN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Royal Bank Of Canada increased their price objective on shares of Biohaven from $22.00 to $23.00 and gave the company an "outperform" rating in a research report on Tuesday...

JPMorgan Chase & Co. Reduces Stake in Biohaven Ltd. $BHVN

JPMorgan Chase & Co. reduced its stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 48.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange...

Biohaven (NYSE:BHVN) Posts Earnings Results, Beats Expectations By $0.32 EPS

Biohaven (NYSE:BHVN - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22...

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial...

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BHVN News

BHVNBiohaven Pharmaceutical Holding Company Ltd